Priority considerations in early laboratory diagnosis of Hepatocellular carcinoma

International Journal of Integrative Biology

Volumn 3, Issue 3, 2008, Pages 196-201

  Abdel Hamid, Nabil Mohie ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

Alpha fetoprotein; Alpha L fucosidase; Gamma glutamyl transferase; Insulin like growth factor II; Transforming growth factor beta

Indexed keywords

ALPHA FETOPROTEIN; ALPHA LEVO FUCOSIDASE; AURORA A KINASE; DECARBOXYPROTHROMBIN; GAMMA GLUTAMYL HYDROLASE; GAMMA GLUTAMYLTRANSFERASE; HEAT SHOCK PROTEIN; MESSENGER RNA; PANCREATITIS ASSOCIATED PROTEIN; PLASMA GLUTAMATE CARBOXYPEPTIDASE; PROTEIN P53; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; EARLY DIAGNOSIS; HUMAN; LABORATORY DIAGNOSIS; LIVER CELL CARCINOMA; PREDICTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

EID: 79955850885     PISSN: 09742816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Abelev GA, sseccritova I, et al. (1967) Embryonal serum α-globulin in cancer patients. Diagnostic value. Int. J. Cancer 2:551-558.
2. Bergstrand CG and Czar, B (1956) Demonstration of a new protein fraction in serum from human fetus. Scand. J. Clin. Lab. Invest. 8: 174-179.
3. Cantarini MC, delaMonte SM, et al. (2006) Aspartyl-Asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatol. 44: 446-457.
4. Cha C, Fong Y, et al. (2003) Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J. Am. Coll. Surg. 197: 753-758.
5. Chawla D, Deorari AK, et al. (2007) Vitamin k1 verus vitamin K3 for prevention of subclinical vitamin deficiency: a randomized controlled trial. Indian Pediatrics 44(17):817-822.
6. Dong ZZ, Yao DF, et al. (2005) Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J. Gastroenterol 11(30): 4655-4660.
7. Dong ZZ, Zou L, et al. (2006) Expression of hepatoma and circulating TGF-B1 mRNA and its clinical values in diagnosis of patients with liver cancer. J. Gastroenterol Hepatol, 21(S2): A172.
8. Dong ZZ, Yao DF, et al. (2007) Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Chinese Journal of Hepatology 15(7):503-508.
9. Fujiyama S, Tanaka M, et al. (2002) Tumor markers in early diagnosis, followup and management of patients with hepatocellular carcinoma. Oncology 62(Suppl 1): 57-63.
10. Furukawa M, Nakanishi T, et al. (1992) Changes of plasma des-gamma-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer 69:31-38.
11. Giardina M, Matarazzo M et al. (1992) Serum α-L-fucosidase:a useful marker in the diagnosis of hepatocellular carcinoma. Cancer 70: 1044-1048.
12. Giardina M, Matarazzo M, et al. (1998) Serum α-L-fucosidase activity and early detection of hepatocellular carcinoma. Cancer 83: 2468-2474.
13. Huisse MG, Leclercq M, et al. (1994) Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas. Cancer 74:1533-1541.
14. Ikoma J, Kaito M, et al. (2002) Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterol 49(43): 235-238.
15. Ishizuka H, Nakayama T et al. (1999) Prediction of the development of hepatocellular carcinoma in patients with liver cirrhosis by the serial determinations of serum α-L-fucosidase activity. Intern. Med. 38: 927-931.
16. Jiang YF, Yang ZH et al. (2002) Recurrence or metastasis of HCC: predictors, early detection and experimental angiogenic therapy. W. J. Gastroenterol 6: 61-65.
17. Jian W, Nianyue W, et al. (2007) A Simple and Specific Method for Detection of Hepatoma Specific GGT by Affinity Chromatography. Laboratory Medicine 38(3): 160-164.
18. Kim YJ, Lee HS, et al. (2003) Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp. Mol. Med. 35:196-202.
19. Koike Y, Shiratori Y, et al. (2001) Desgamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma:a prospective analysis of 227 patients. Cancer 91: 561-569.
20. Kulpa J and Rychlik U (2004) Tumor markers in laboratory diagnosis (in Polish). Badanie i Diagnoza 10: 9-14.
21. Lu Y, Wu L, et al. (2008) Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis. Int. 7: 174-178
22. Ma J, Gong Q et al. (2000) Combined five tumor markers in detecting primary hepatic carcinoma (Chinese with English summary). Zhonghua Wai Ke Za Zhi 38: 14-16.
23. Madalinska K, Jonczyk M, et al. (2005) Serological markers for hepatocellular carcinoma-modern trends. Centr Europ. J. of Immunol. 30(1-2): 32-36.
24. Matsumura M, Shiratori Y et al. (1999) Presence of α-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma. J. Hepatol. 31: 332-339.
25. Meng SD, Song J, et al. (2002) Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides. J. Immunol. Methods 264: 29-35.
26. Okuda H, Obata H, et al. (1987) Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J. Hepatol. 4(3): 357-363.
27. Pasche B (2001) Role of transforming growth factor beta in cancer. J. Cell Physiol. 186: 153-168.
28. Peto J (2001) Cancer epidemiology in the last century and the next decade. Nature 411: 390-395.
29. Plebani M and D'Amico DF (2005) Role of blood AFPmRNA and tumor grade in preoperative prognostic evaluation of patients with hepatocellular carcinoma. W. J. Gastroenterol 11: 6920-6925.
30. Qin LX and Tang ZY (2004) Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J. Cancer Res. Clin. Oncol. 130: 497-513.
31. Schlichtholz B, Tredaniel J, et al. (1994) Analysis of p53 antibodies in sera of patients with lung carcinoma: the fine immunodominant regions in the p53 protein. Br. J. Cancer 69: 809-816.
32. Shi M, Zhang CQ, et al. (2004) Micrometastsis of solitary hepatocellular carcinoma and appropriate resection margin. W. J. Gastroenterol 28: 376-381.
33. Soussi T, Legros Y, et al. (1994) Multifunctional analysis of p53 alteration in human cancer: a review. Int. J. Cancer 57: 1-9.
34. Srivatanakul P, Sriplung H et al. (2004) Epidemiology of liver cancer: an overview. Asian Pac. J. Cancer Prev. 5:118-125.
35. Suehiro T, Matsumata T, et al. (1995) Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 117(6): 682-691.
36. Suzuki M, Shiraha H, et al. (2005) Des γ-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. The J. of Biol. Chem. 280(8): 6409-6415.
37. Sztefko K, Kosowski K, et al. (1998) Alpha L-fucosidase activity in patients with ductal cholilithiasis (in Polish). Przeglad Lekaraski 55: 124-127.
38. Tamano M, Sugaya H, et al. (2002) Serum and tissue PIVKA-II expression reflects the biological malignant potential of small hepatocellular carcinoma. Hepatol Res. 22(4): 261-269.
39. Wang Z, Ruan WB, et al. (2003) Expression of IGF-II in experimental hepatocellular carcinoma and its significance in early diagnosis. W. J. Gastroenterol 9: 267-270.
40. Wang XH, Qin Y, et al. (2005) Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 54: 971-980.
41. Wawrzynowicz-Syczewska M, Matievskaya NV, et al. (2003) Diagnostic efficacy of α-fetoprotein (AFP) versus L3 fraction of AFP in discrimination between liver cirrhosis and hepatocellular carcinoma of viral origin. In: 12th Falk Liver Week Liver Diseases: Advances in Treatment and Prevention, Freiburg: (10)17-19.
42. Yanhong L, Junzhu W, et al. (2007) Diagnosis of hepatocellular carcinoma by using methylation specific-PCR. Wuhan Univ J. Natural. Sci. 12(3): 558-562.
43. Yao DF, Dong ZZ, et al. (2000) Peripheral blood AFP-mRNA amplification in the diagnosis of hepatocellular carcinoma. Clin. J. Gen. Sur. 15: 474-477.
44. Yao DF, Jiang DR, et al. (2000) Abnormal expression of hepatoma specific γ-glutamyltransferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 88: 761-769.
45. Yao DF, Dong ZZ, et al. (2004) Abnormal expression of hepatoma-derived gamma glutamyl transferase subtyping and its alteration for carcinogenesis of hepatocytes. Hepatobil. Pancr. Dis. Int. 3:564-570.
46. Yao D, Dong Z et al. (2007) Specific molecular markers in hepatocellular carcinoma. Hepatobil. Pancr. Dis. Int. 6(3): 241-247.
47. Yoshida S, Kurokohchi K, et al. (2002) Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha fetoprotein in patients with hepatocellular carcinoma. Int. J. Oncol. 20: 305-309
48. Yuen MF and Lai CL (2005) Serological markers of liver cancer. Best Pract. Res. Clin. Gastroenterol 19:91-99.
49. Zinkin NT, Grall F, et al. (2008) Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin. Cancer Res. 14(2):470-7.